



Attorney Docket No. VPI/02-116 US

JFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/700,333

Confirmation No.: 5159

Filing Date: November 3, 2003

Examiner: Venkataraman Balasubramanian

Group Art Unit: 1624

Applicants: Mark Ledeboer et al.

For: COMPOSITIONS USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES

June 28, 2006
Cambridge, Massachusetts

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

(a) Pursuant to 37 C.F.R. §1.56, it is requested that the documents listed on the accompanying Form 1449/PTO be considered and made of record in the above-identified patent application.

- Copies of references Citation Nos. A1; B6-B7 are attached.
- Copy(ies) of references Citation No(s). _____ was/were filed in application U.S. Application No(s). _____ filed _____, from which this application claims priority under 35 U.S.C. § 120.
- A copy of the International Search Report received in the corresponding PCT Application No. _____ is attached herewith.

(b) No fee is believed due because:

- The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- The Information Disclosure Statement is being concurrently filed with the above-identified application.
- The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
- The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.

Applicants: Mark Ledeboer et al.

Application No.: 10/700,333

- (c) The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and
- Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or
- The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- (d) The Information Disclosure Statement is being filed on or before the payment of the issue fee; and
- Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
- No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and
- The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED.

Applicants: Mark Ledeboer et al.
Application No.: 10/700,333

Respectfully submitted,

Karen E. Brown

Karen E. Brown, Reg. No. 43,866
Attorney for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6168
Fax: (617) 444-6483
Customer No.: 27916

I hereby certify that this correspondence and any documents referred to as attached hereto are being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to:
Mail Stop Amendment, Commissioner for Patents,
P.O. Box 1450, Alexandria, VA 22313-1450 on June 28, 2006.

Lisa M. Romano

Signature

Lisa Romano



Modified Form 1449/PTO

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/700,333
Filing Date	November 3, 2003
First Named Inventor	Mark Ledebot
Group Art Unit	1624
Examiner Name	Venkataraman Balasubramanian
Attorney Docket Number	VPI/02-116 US

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date/ Publication date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	US2004/0176271 A1	September 9, 2004	Vertex Pharmaceuticals Incorporated	514	2	11/5/2003

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B6	WO 03/030909 A1	Bayer Corporation	17 April 2003	
	B7	WO 02/079193 A1	Cyclacel Limited	10 October 2002	

OTHER NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application,
U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120
(continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.